Risk factors for endometrial cancer among women with a BRCA1 or BRCA2 mutation: a case control study

BRCA mutation carriers may use tamoxifen for breast cancer prevention or treatment. Hormone replacement therapy is often prescribed after surgical menopause and oral contraceptives are recommended for ovarian cancer prevention. The objective of this study was to assess the impact of these medication...

Full description

Saved in:
Bibliographic Details
Published in:Familial cancer 2015-09, Vol.14 (3), p.383-391
Main Authors: Segev, Yakir, Rosen, Barry, Lubinski, Jan, Gronwald, Jacek, Lynch, Henry T., Moller, Pal, Kim-Sing, Charmaine, Ghadirian, Parviz, Karlan, Beth, Eng, Charis, Gilchrist, Dawna, Neuhausen, Susan L., Eisen, Andrea, Friedman, Eitan, Euhus, David, Ping, Sun, Narod, Steven A.
Format: Article
Language:English
Subjects:
Adult
Aged
Biomedical and Life Sciences
Biomedicine
BRCA1 Protein - genetics
BRCA2 Protein - genetics
Cancer Research
Case-Control Studies
Endometrial Neoplasms - genetics
Endometrial Neoplasms - prevention & control
Epidemiology
Estrogen Replacement Therapy - methods
Female
Genetic Predisposition to Disease
Heterozygote
Human Genetics
Humans
Hysterectomy
Middle Aged
Mutation
Odds Ratio
Original Article
Ovariectomy
Risk Factors
Tamoxifen - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BRCA mutation carriers may use tamoxifen for breast cancer prevention or treatment. Hormone replacement therapy is often prescribed after surgical menopause and oral contraceptives are recommended for ovarian cancer prevention. The objective of this study was to assess the impact of these medications and other risk factors on endometrial cancer risk in BRCA carriers. Women with a BRCA1 or BRCA2 mutation were identified from a registry of mutation carriers. Cases were 83 women who had a diagnosis of endometrial cancer. Controls were 1027 matched women who did not develop endometrial cancer and who had an intact uterus. All women completed a baseline questionnaire, which included questions about ages at menarche and menopause, oral contraceptive use, hormone replacement therapy use, hysterectomy, oophorectomy, breast cancer history and tamoxifen use. We estimated the odds ratio associated with each risk factor in a multivariate analysis. No differences were found between cases and controls in terms of age at menarche, BMI, smoking, or oral contraceptive use. In a multivariate analysis, for women taking estrogen-only hormone replacement therapy, the odds ratio was 0.23 (95 % CI 0.03–1.78, p  = 0.16), and for women taking progesterone-only hormone replacement therapy the odds ratio was 6.91 (95 % CI 0.99–98.1, p  = 0.05). The adjusted odds ratio for endometrial cancer associated with a history of tamoxifen use was 3.50 (95 % CI 1.51–8.10, p  = 0.003). The observed increased risk of endometrial cancer associated with progesterone-only therapy merits further study.
ISSN:1389-9600
1573-7292
DOI:10.1007/s10689-015-9798-8